Ultragenyx Pharmaceutical Price Target Skyrockets to $80.00

Ultragenyx Pharmaceutical (NASDAQ:RARE) saw its price target raised to $80.00 by analysts at JPMorgan Chase & Co.

The move indicates a potential upside of 211.04% from the stock's current price, which is $25.72 per share.

This update comes after several other firms have also issued reports on RARE. HC Wainwright reaffirmed its 'buy' rating and set a target price of $50.00, while Canaccord Genuity Group raised their target from $81.00 to $83.00 and gave the company an 'overweight' rating.

Despite the positive outlook from some analysts, others have been more cautious, with Guggenheim dropping its target price on RARE from $43.00 to $35.00 and setting a 'buy' rating for the company.